EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Translational Perspective on Mechanisms and Clinical Implications

Isabella Gómez-Maldonado iD, Andrea Rodríguez-Arana iD, Alejandro Tamayo-Pinzón iD, Juan Esteban Albornoz-Suárez, María José López-Franco, Juan Andrés Mejia-Manrique, Juan Jacobo Forero-Caycedo iD, Luis Carlos Rojas-Rodríguez iD, Natalia Buitrago-Ricaurte iD, Mariana Gaviria-Carrillo iD, Jesús Rodríguez-Quintana iD, Carlos Alberto Calderón-Ospina iD

International Journal of Molecular Sciences · 08.08.2026 · 27 (16) · 7108

DOI: 10.3390/ijms27167108 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.08.2026. Verfasst von Isabella Gómez-Maldonado und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Group in Applied Biomedical Sciences (UR Biomed), School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Cardiology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obstructive sleep apnea (OSA) affects nearly one billion adults worldwide and involves mechanical upper-airway obstruction alongside metabolic dysfunction, systemic inflammation, and gut–brain axis disruption. Despite the efficacy of continuous positive airway pressure (CPAP), suboptimal long-term adherence highlights the need for complementary pharmacological strategies. This narrative review synthesizes preclinical and clinical evidence on GLP-1-based therapies, encompassing selective GLP-1 receptor agonists and tirzepatide, a dual GIP/GLP-1 receptor agonist, in obesity-associated OSA. Preclinical studies show that GLP-1 receptor activation can reduce visceral adiposity, attenuate pro-inflammatory signaling, improve glucose and lipid metabolism, and modulate hypothalamic appetite circuits. However, the only identified murine study evaluating liraglutide during intermittent hypoxia—an experimental model of one component of OSA rather than the complete disorder—did not reverse hypoxia-induced insulin resistance, indicating that persistent intermittent hypoxia may limit metabolic improvement in that model. Clinically, liraglutide and tirzepatide have reduced the apnea–hypopnea index (AHI) and improved several cardiometabolic outcomes. Numerically larger AHI reductions were reported in the tirzepatide trials, although no head-to-head comparison with selective GLP-1 receptor agonists is available. Tirzepatide is approved by the U.S. Food and Drug Administration for moderate-to-severe OSA in adults with obesity, together with a reduced-calorie diet and increased physical activity, and may be used without concomitant positive airway pressure in eligible patients or as an adjunct to ongoing therapy. The observed respiratory benefits appear to be mediated predominantly by weight loss and related reductions in mechanical and metabolic burden. Evidence supporting additional weight-independent mechanisms remains insufficient, and longer-term mechanistic studies in broader populations are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveGlucagon-Like Peptide-1 Receptor AgonistsHumansAnimalsTirzepatideLiraglutideGlucagon-Like Peptide-1 ReceptorObesityTranslational Research, Biomedical

Stichwörter der Autor:innen

GLP-1 receptor agonistsGLP-1-based therapiesapnea–hypopnea indexintermittent hypoxiametabolic dysfunctionobesityobstructive sleep apneatirzepatidevisceral adiposity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsTirzepatideLiraglutideGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Research Group in Applied Biomedical Sciences (UR Biomed), School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.
  • Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.
  • Neuroscience Research Group (NeURos), NeuroVitae Center for Neuroscience, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.
  • Fundación CardioInfantil-Instituto de Cardiología, Bogota 111156, Colombia.
  • Hospital Universitario Mayor Mederi, Bogota 111411, Colombia.

ORCID-Profile: Isabella Gómez-Maldonado, Andrea Rodríguez-Arana, Alejandro Tamayo-Pinzón, Juan Jacobo Forero-Caycedo, Luis Carlos Rojas-Rodríguez, Natalia Buitrago-Ricaurte, Mariana Gaviria-Carrillo, Jesús Rodríguez-Quintana, Carlos Alberto Calderón-Ospina

Förderung

  • Institute of Cardiology

Zitieren

APA

Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., López-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., Rodríguez-Quintana, J., & Calderón-Ospina, C. A. (2026). GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Translational Perspective on Mechanisms and Clinical Implications. International Journal of Molecular Sciences, 27(16), 7108. https://doi.org/10.3390/ijms27167108

Vancouver

Gómez-Maldonado I, Rodríguez-Arana A, Tamayo-Pinzón A, Albornoz-Suárez JE, López-Franco MJ, Mejia-Manrique JA, et al. GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Translational Perspective on Mechanisms and Clinical Implications. International Journal of Molecular Sciences. 2026;27(16):7108. doi:10.3390/ijms27167108

BibTeX
@article{GmezMaldonado2026,
  author = {Gómez-Maldonado, Isabella and Rodríguez-Arana, Andrea and Tamayo-Pinzón, Alejandro and Albornoz-Suárez, Juan Esteban and López-Franco, María José and Mejia-Manrique, Juan Andrés and Forero-Caycedo, Juan Jacobo and Rojas-Rodríguez, Luis Carlos and Buitrago-Ricaurte, Natalia and Gaviria-Carrillo, Mariana and Rodríguez-Quintana, Jesús and Calderón-Ospina, Carlos Alberto},
  title = {GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Translational Perspective on Mechanisms and Clinical Implications},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7108},
  doi = {10.3390/ijms27167108}
}
Kostenlos starten →